Parkinson's disease
Conditions
Interventions
This is a clinical, randomized, controlled, crossover, double-blind study. 14 people with Parkinson's disease and 14 neurologically healthy people (control group – CG) will participate in this study.
application of sessions with different oxygen availability
gait and blood assessment immediately after the sessions
identification of sleep quality during the recovery night
gait and blood assessment 24 hours after the session, and identification of sleep quality during the night following the test, that is, 24 hours after the session. The order of sessions with different
Sponsors
Universidade Estadual Paulista Júlio de Mesquita Filho
Universidade Estadual Paulista Júlio de Mesquita Filho
Eligibility
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: Age equal to or over 50 years old. Both genders. Have independent mobility without the aid of auxiliary devices (e.g., cane). No history of orthopedic or vision problems that would make it impossible to comply with the experimental protocol. No uncontrolled cardiovascular, metabolic or inflammatory problems. Especially for people with Parkinson's Disease, inaddition: have a diagnosis from a private neurologist that indicates the presence of idiopathic Parkinson's Disease determined by the London Brain Bank; be under stable drug treatment with Levodopa for at least 3 weeks and have not undergone brain surgery or deep brain stimulation to treat Parkinson's Disease
Exclusion criteria
Exclusion criteria:
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Primary
| Measure | Time frame |
|---|---|
| Investigate the acute effects (immediately and 24 hours after exposure) of isolated application of intermittent hypoxia in individuals with Parkinson's Disease on: gait: spatiotemporal parameters (e.g., step length, width, and duration) and lower limb muscle activity; sleep: quantitative variables (e.g., bedtime, wake-up time, total time in bed, total sleep time, sleep latency, sleep efficiency) and qualitative aspects (e.g., assessed through the Likert scale, and blood biomarkers (e.g., concentration of Brain drive neurotropic factor, IL-6, and iron).;Sistematically review the body of knowledge regarding the responses induced by hypoxia exposure in individuals with PD | — |
Countries
Brazil
Contacts
Public ContactFabio Barbieri
Universidade Estadual Paulista Júlio de Mesquita Filho
Outcome results
None listed